Alpha Fusion Inc. is pioneering the development of innovative cancer treatments through the use of Astatine-211 (211 At), a unique alpha-emitting isotope. This technology is central to their approach, known as Targeted Alpha Therapy (TAT), which selectively targets cancer cells while minimizing damage to surrounding healthy tissues. The therapeutic potential of 211 At lies in its ability to be directly bonded to ligands that accumulate in cancerous tissues, allowing for precise delivery of treatment. With a half-life of approximately 7.2 hours, 211 At enables rapid elimination of radiation from the body, reducing side effects and allowing for multiple administrations in a shorter treatment timeframe. This method not only enhances the effectiveness of cancer therapies but also alleviates the need for specialized radiation therapy facilities, making treatment more accessible to patients.

The company is currently advancing several clinical pipelines, including αf-001 and αf-002, which leverage the properties of 211 At for treating thyroid and prostate cancers, respectively. αf-001 aims to provide a less burdensome treatment option for patients with refractory thyroid cancer, while αf-002 targets prostate-specific membrane antigen (PSMA) in hormone-refractory prostate cancer, showing promising results in preclinical evaluations. By focusing on the unique characteristics of Astatine-211, Alpha Fusion Inc. is positioned to address significant unmet medical needs in cancer treatment, offering hope to patients with limited options.

Japan

Alpha Fusion Inc. is a clinical-stage startup committed to transforming cancer treatment through the design and development of powerful and precise radiopharmaceuticals. Our radiopharmaceuticals utilize Astatine-211 (211At), alpha-emitting particles that are both effective against cancer and safe for patients. This innovation will significantly impact cancer patients who currently have limited treatment options.

Alpha Fusion

Company Details